BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18339472)

  • 1. Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
    Lee SE; Chung JS; Han BK; Park CS; Moon KH; Byun SS; Choe G; Hong SK
    Eur Urol; 2008 Dec; 54(6):1324-32. PubMed ID: 18339472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Zanni G; Suardi N; Capitanio U; Colombo R; Bertini R; Freschi M; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2011 Apr; 107(8):1243-9. PubMed ID: 20883480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection.
    Salonia A; Briganti A; Gallina A; Karakiewicz P; Shariat S; Freschi M; Zanni G; Capitanio U; Bosi E; Rigatti P; Montorsi F
    Urology; 2009 Apr; 73(4):850-5. PubMed ID: 19038425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
    Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of extraprostatic extension by prostate specific antigen velocity, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
    Nishimoto K; Nakashima J; Hashiguchi A; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M; Murai M
    Int J Urol; 2008 Jun; 15(6):520-3. PubMed ID: 18422574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Editorial comment on: preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.
    Salonia A
    Eur Urol; 2008 Dec; 54(6):1331-2. PubMed ID: 18339473
    [No Abstract]   [Full Text] [Related]  

  • 7. Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy.
    Imamoto T; Suzuki H; Fukasawa S; Shimbo M; Inahara M; Komiya A; Ueda T; Shiraishi T; Ichikawa T
    Eur Urol; 2005 Mar; 47(3):308-12. PubMed ID: 15716191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
    Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radial distance of extraprostatic extension measured by ocular micrometer is an independent predictor of prostate-specific antigen recurrence: A new proposal for the substaging of pT3a prostate cancer.
    Sung MT; Lin H; Koch MO; Davidson DD; Cheng L
    Am J Surg Pathol; 2007 Feb; 31(2):311-8. PubMed ID: 17255778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy.
    Salonia A; Gallina A; Briganti A; Suardi N; Capitanio U; Abdollah F; Bertini R; Freschi M; Rigatti P; Montorsi F
    Cancer; 2011 Nov; 117(22):5029-38. PubMed ID: 21495024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of extraprostatic extension in men with biopsy Gleason score of 8 or greater.
    Nakanishi H; Troncoso P; Babaian RJ
    J Urol; 2008 Dec; 180(6):2441-5; discussion 2445-6. PubMed ID: 18930495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
    Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
    Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination.
    Tsuzuki T; Hernandez DJ; Aydin H; Trock B; Walsh PC; Epstein JI
    J Urol; 2005 Feb; 173(2):450-3. PubMed ID: 15643200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.
    Massengill JC; Sun L; Moul JW; Wu H; McLeod DG; Amling C; Lance R; Foley J; Sexton W; Kusuda L; Chung A; Soderdahl D; Donahue T
    J Urol; 2003 May; 169(5):1670-5. PubMed ID: 12686805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative prediction of final pathological features is not improved by the free-to-total prostate-specific antigen ratio in Japanese men with clinically localized prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Feb; 12(2):182-6. PubMed ID: 15733113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of neural networks and logistic regression analysis for predicting pathological stage in men undergoing radical prostatectomy: a population based study.
    Borque A; Sanz G; Allepuz C; Plaza L; Gil P; Rioja LA
    J Urol; 2001 Nov; 166(5):1672-8. PubMed ID: 11586200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.